Rosetta Genomics (ROSG) Secures Medicare Reimbursement Pricing for miRv
Tweet Send to a Friend
Up)
Rosetta Genomics Ltd. (NASDAQ: ROSG) today announced that the designated Medicare Administrative Contractor for the Company's miRview mets assay has determined the assay to be reasonable and necessary for the diagnosis of cancers of unknown origin in a specified setting and has established a reimbursement rate for the assay.
The coverage decision can be found at the following link: https://www.novitas-solutions.com/bulletins/all/news-06152012.html. The miRview mets assay accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The coverage decision can be found at the following link: https://www.novitas-solutions.com/bulletins/all/news-06152012.html. The miRview mets assay accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Depomed (DEPO) Reports Submission of ANDA for Generic Zipsor
- 3D Systems (DDD) Will Bring Geomagic Solutions to DMC in Shanghai
- Erickson Air-Crane (EAC) Says Flour Extends Contract
Create E-mail Alert Related Categories
Corporate News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
